[Click eStock] "Hanmi Pharm Exceeds Q4 Earnings Expectations"

[Asia Economy Reporter Park Jihwan] Daishin Securities announced on the 17th that it expects Hanmi Pharm's Q4 2023 earnings to exceed market expectations. The investment opinion remains 'Buy,' but the target price was lowered by 15% to 340,000 KRW.

Researcher Lim Yunjin of Daishin Securities stated, "Q4 earnings are expected to surpass expectations due to royalty income and growth of the subsidiary Beijing Hanmi." He added, "On a consolidated basis, sales are projected to increase by 15.0% to 318.9 billion KRW, but operating profit is expected to decrease by 11.2% to 37.2 billion KRW."

This year, key investment points include FDA approval of new drug pipelines and clinical trial result announcements. Rolontis is understood to be supplementing data after receiving a CRL in August last year. A BLA resubmission is planned for Q1 this year, with a reinspection of the Pyeongtaek bio plant expected within the year, aiming for a U.S. launch in 2023.

Poziotinib completed its New Drug Application (NDA) submission in December last year for HER2 exon20 mutant NSCLC. It was designated as a Fast Track, shortening the approval review to six months, raising expectations for conditional U.S. approval as early as the second half of this year.

Additionally, the mid-term results announcement within the year for the Dual agonist's Phase 2 clinical trial, conducted by partner Merck, is also anticipated. Researcher Lim emphasized, "The Triple agonist's major Phase 2 clinical trial results in the U.S. are expected within the year," adding, "If positive results are confirmed, opportunities for technology transfer are likely to expand."

This content was produced with the assistance of AI translation services.